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A B S T R A C T
Astrocytes exert neuroprotective effects through production of antioxidant molecules and neurotrophic factors.
A recent study showed that stimulation of astrocyte serotonin 1A (5-HT1A) receptors promotes astrocyte pro-
liferation and upregulation of the antioxidant molecules metallothionein (MT)-1,2, which protect dopaminergic
neurons against oxidative stress. Rotigotine, an anti-parkinsonian drug, can bind to dopamine and 5-HT1A re-
ceptors. In this study, we examined neuroprotective effects of rotigotine in models of Parkinson’s disease and
involvement of astrocyte 5-HT1A receptors in neuroprotective effects of rotigotine against dopaminergic neu-
rodegeneration. Rotigotine increased the number of astrocytes and MT-1,2 expression in cultured astrocytes.
Pretreatment with conditioned media from rotigotine-treated astrocytes significantly inhibited 6-hydro-
xydopamine (6-OHDA)-induced dopaminergic neurotoxicity. These effects were completely blocked by a 5-
HT1A antagonist or MT-1,2 specific antibody. Subcutaneous administration of rotigotine increased MT-1,2 ex-
pression in striatal astrocytes and prevented reduction of dopaminergic neurons in the substantia nigra of a 6-
OHDA-lesioned mouse model of Parkinson’s disease. These effects were blocked by co-administration with a 5-
HT1A antagonist. These results suggest that rotigotine exerts neuroprotective effects through upregulation of MT
expression in astrocytes by targeting 5-HT1A receptors. Our findings provide a possible therapeutic application
of rotigotine to prevent dopaminergic neurodegeneration in Parkinson’s disease.
1. Introduction
Parkinson's disease (PD) is a progressive neurodegenerative disease.
Motor symptoms such as tremor, bradykinesia, and rigidity are induced
by degeneration of dopaminergic neurons in the substantia nigra pars
compacta (SNpc), which causes depletion of dopaminergic nerve
terminals and dopamine (DA) content in the striatum (Chen et al.,
2012; Dauer and Przedborski, 2003; Halliday et al., 1996). PD patients
also develop non-motor symptoms including psychological manifesta-
tions such as depression, and autonomic disorders such as orthostatic
hypotension and constipation (Berg et al., 2013; Grinberg et al., 2010;
Singaram et al., 1995). Although pathogenesis in sporadic PD has not
been characterized, oxidative stress is thought to be an important
neurotoxic factor (Wang and Michaelis, 2010). Major medications used
to treat PD patients provide dopaminergic therapy for managing motor
disability. Therefore, it is essential to develop neuroprotectants that can
prevent or delay progression of dopaminergic neurodegeneration.
Astrocytes are abundant neuron-supporting glial cells which com-
prise blood brain barrier, and regulate cerebral blood flow and synaptic
function (Abbott et al., 2006; Araque et al., 1999; Attwell et al., 2010;
Gordon et al., 2011; Koehler et al., 2009). In addition, astrocytes exert
neuroprotective effects by producing antioxidants and neurotrophic
factors, and by taking up excess extracellular glutamate (Banker, 1980;
Dringen, 2000; Dringen and Hirrlinger, 2003). Recently, various studies
have demonstrated neuroprotective actions of astrocytes (Drukarch
et al., 1998; Jewett et al., 2017; Miyazaki and Asanuma, 2016; Nam
et al., 2015). We previously reported that striatal astrocytes produced
and secreted antioxidant molecules, metallothioneins (MTs), in re-
sponse to oxidative stress, resulting in protection of dopaminergic
neurons (Miyazaki et al., 2011). Stimulation of astrocyte serotonin 1A
(5-HT1A) receptors enhances astrocyte proliferation and upregulates
MT expression in striatal astrocytes, resulting in protection of dopa-
minergic neurons in a mouse model of PD (Miyazaki et al., 2013). These
findings indicated that astrocyte 5-HT1A receptors may be a novel
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target for neuroprotection.
Rotigotine, a DA agonist, is used to treat PD. Rotigotine binds to all
DA receptor subtypes (D1-D5), but has particularly high affinity for D2,
D1, and D3 receptors (Wood et al., 2015). In addition to acting as a DA
agonist, rotigotine is also a 5-HT1A partial agonist (Scheller et al.,
2009). In the present study, we examined neuroprotective effects of
rotigotine in a 6-hydroxydopamine (6-OHDA)-lesioned mouse PD
model, and explored involvement of astrocyte 5-HT1A receptors in
neuroprotective actions of rotigotine.
2. Materials and methods
2.1. Animals and animal care
All experimental procedures were conducted following the
Guideline for Animal Experiments of Okayama University Advanced
Science Research Center, and were approved by the Animal Care and
Use Committee of Okayama University Advanced Science Research
Center (approval reference number OKU-2016167; OKU-2019542).
Male Crl:CD1 (ICR) mice and pregnant Sprague-Dawley (SD) rats were
purchased from Charles River Japan Inc. (Yokohama, Japan). Mice and
rats were housed under temperature- and humidity-controlled condi-
tion, which was maintained on a 12 h light/dark cycle with free access
to food and water in Okayama University Advanced Science Research
Center.
2.2. Cell culture
Primary cultured neurons and astrocytes were prepared from the
mesencephalon and striata of SD rat embryos at 15 days of gestation
using a previously described method (Miyazaki et al., 2013). To collect
astrocyte conditioned media (ACM) and examine effects of rotigotine
on MT expression in astrocytes, astrocyte cultures were prepared using
striata of rat embryos. Dissected striata were cut into small pieces with
scissors, and then incubated in 0.125% trypsin-EDTA (Thermo Fisher
Scientific, Waltham, MA, USA) at 37 °C for 15 min. After centrifugation
(1500 g for 3 min), the cell pellet was treated with 0.004% DNase I
(Sigma-Aldrich, St. Louis, MO, USA) containing 0.003% trypsin in-
hibitor (Thermo Fisher) at 37 °C for 7 min. Following centrifugation
(1500 g for 3 min), cells were plated in Dulbecco's Modified Eagle's
Medium (DMEM) (Invitrogen, San Diego, CA, USA) containing 10%
fetal bovine serum (FBS) (Sigma-Aldrich) at a density of 2 × 105 cells/
cm2 on poly-D-lysine-coated 6-well plates (Falcon, Corning, NY, USA).
Cells were cultured for 4–7 days in the same medium, then subcultured
to obtain enriched astrocyte cultures. Subcultured cells were plated at a
density of 3.6 × 104 cells/cm2 onto 6-well culture plates (Falcon) for
preparation of conditioned media or nuclear protein extraction, or at a
density of 2 × 104 cells/cm2 onto four-chambered glass culture slides
coated with poly-D-lysine (Falcon) for immunohistochemical analysis.
After 7 days of culture, greater than 95% cells expressed astrocyte
marker proteins.
To prepare enriched neuronal cultures, the mesencephalon was
treated with 0.125% trypsin-EDTA and 0.004% DNase I containing
0.003% trypsin inhibitor as described above. Cells were plated in
DMEM containing 10% FBS at a density of 2 × 105 cells/cm2 on poly-D-
lysine-coated four-chambered culture slides (Falcon). The medium was
replaced within 24 h with fresh medium supplemented with 2 μM cy-
tosine-β-D-arabinofuranoside (Ara-C) (Sigma-Aldrich) to inhibit re-
plication of glial cells, and incubated for 6 days. Ninety-five percent of
cells were microtubule-associated protein 2-positive neurons, and 1% of
the cells were tyrosine hydroxylase (TH)-positive dopaminergic cells.
Mesencephalic neuronal and striatal astrocyte cocultures were pre-
pared by culturing striatal astrocytes for 4 days, then seeding astrocytes
at a density of 4 × 104 cells/cm2 directly onto mesencephalic neurons
that had been cultured on four-chambered culture slides for 4 days. All
cultures were maintained at 37 °C in a 5% CO2 atmosphere.
2.3. Preparation of astrocyte conditioned medium (ACM)
Striatal astrocytes were plated onto 6-well plates and grown in DMEM
containing 10% FBS for 7 days. Astrocyte conditioned media (ACM) were
prepared by treating astrocytes with 1 μM rotigotine (Sigma-Aldrich) (ro-
tigotine-ACM), 10 nM N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-
(2-pyridinyl) cyclohexanecarboxamide maleate salt (WAY100635, a
5-HT1A receptor antagonist, Sigma-Aldrich) (WAY100635-ACM),
WAY100635 and rotigotine (WAY100635+rotigotine-ACM), or vehicle
(control-ACM) for 24 h. Conditioned media were collected, centrifuged at
3000 g for 3 min to remove cellular debris, and supernatants were stored at
−80 °C until use.
2.4. Cell treatments
Rotigotine was prepared fresh in dimethylsulfoxide (DMSO) (Sigma-
Aldrich) for each experiment, then diluted to final concentration in
medium (final concentration of DMSO: 0.1% v/v). To investigate the
effects of rotigotine on astrocyte proliferation, striatal astrocytes were
treated with rotigotine (0.01, 0.1, or 1 μM) one day after subculture for
24 h, and then counterstained with Hoechst 33342 nuclear stain. To
examine effects of rotigotine on MT-1,2 expression in astrocytes, astro-
cytes cultured for 7 days were treated with rotigotine (0.01, 0.1, or 1 μM)
for 24 h. To study the involvement of the 5-HT1A receptor in rotigotine-
induced MT-1,2 up-regulation and Nrf2 nuclear translocation, astrocytes
were treated with rotigotine (1 μM) dissolved in phosphate buffered
saline (PBS) with or without WAY100635 (10 nM) for 24 h or 6 h re-
spectively. Enriched neuronal cultures and neuron-astrocyte cocultures
were treated with rotigotine (1 μM) for 24 h. After culture media were
changed to fresh media, these cells were exposed to 10–150 μM 6-OHDA
(Sigma-Aldrich) for 24 h. To examine whether neuroprotection by roti-
gotine against 6-OHDA-induced neurotoxicity was mediated by astro-
cytes, enriched neuronal cultures were treated with control- or
Abbreviations
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rotigotine-ACM for 24 h followed by 6-OHDA exposure. Involvement of
astrocyte 5-HT1A receptors in neuroprotection by rotigotine was con-
firmed by treatment with WAY100635+rotigotine-ACM. For neu-
tralization assay, an anti-MT-1,2 antibody (DAKO Cytomation, Glostrup,
Denmark) was preincubated with rotigotine-ACM (1:250; 200 μg/ml) for
1 h at room temperature (RT), then applied to the neuronal cultures.
After 24 h treatment with ACM, or rotigotine-ACM with or without the
antibody, culture media were exchanged for fresh media, and neurons
were exposed to 6-OHDA (25 μM) for 24 h. All ACM contained 2 μM Ara-
C throughout the neuronal culture treatment period.
2.5. Treatment of mice with rotigotine
Healthy male ICR mice weighing 38–42 g (8-week-old) were in-
jected subcutaneously with rotigotine (0.125, 0.25, or 0.5 mg/kg) dis-
solved in vehicle 2% DMSO in corn oil (NACALAI TESQUE, INC., Kyoto,
Japan) once per day for 7 days. All animals were arbitrarily allocated to
groups by the experimenter. One day after the final injection of roti-
gotine, mice were perfused transcardially with 4% paraformaldehyde
(PFA) (NACALAI TESQUE) for immunohistochemical analysis under
deep pentobarbital anesthesia (80 mg/kg, i.p.).
2.6. 6-OHDA-lesioned parkinsonian mice and drug treatment
Male ICR mice weighing 38–42 g (8-week-old) were anesthetized by
inhalation of isoflurane (Pfizer, Tokyo, Japan) and placed in a stereo-
taxic apparatus (Narishige, Tokyo, Japan). All mice received unilateral
intrastriatal injections of 6-OHDA (7 μg/site, dissolved in 1 μl of 0.9%
saline containing 0.1% ascorbic acid; Sigma-Aldrich) into three sites in
the right striatum at the following coordinates: A +1.2 mm, L
+2.0 mm, V +3.0 mm; A +0.9 mm, L +1.4 mm, V +3.0 mm; A
+0.5 mm, L +2.0 mm, V +3.0 mm from the bregma, according to a
mouse brain atlas (Franklin and Paxinos, 1997). The injection rate was
1 μl/2 min. After injection, the syringe was left in the striatum for an
additional 3 min before being retracted slowly. Two weeks after 6-
OHDA injections, mice that exhibited asymmetric rotation behavior
towards the contralateral side (> 30 turns/min) after 0.5 mg/kg apo-
morphine injection (Sigma-Aldrich) were determined to have devel-
oped hemi-parkinsonism. One week after the apomorphine test (3
weeks after 6-OHDA injection), all parkinsonian animals were arbi-
trarily allocated to groups by the experimenter. Parkinsonian mice were
subcutaneously injected with rotigotine (0.125, 0.25 or 0.5 mg/kg/day)
or vehicle 2% DMSO in corn oil for 7 days. To examine whether
agonism of 5-HT1A by rotigotine was involved in neuroprotective ef-
fects, parkinsonian mice were intraperitoneally injected with the 5-
HT1A antagonist WAY100635 (0.25, 0.5 mg/kg/day, Sigma-Aldrich)
dissolved in saline 1 h prior to rotigotine treatment. The following
exclusion criteria were applied: more than 10% severe weight loss,
severe behavioral deficits (paralysis, convulsions), or infections. No
animal met the exclusion criteria during the study. One day after final
injections, mice were perfused transcardially with 4% PFA for im-
munohistochemical analysis under deep pentobarbital anesthesia
(80 mg/kg, i.p.). For Western blot analysis and ELISA, mice were per-
fused with ice-cold saline under deep anesthesia, and ventral midbrain
and striatum tissues were dissected out immediately.
2.7. Immunohistochemistry
Cells on chamber slides were fixed with 4% PFA for 20 min at RT,
blocked with 2.5% normal goat serum for 20 min, and reacted with the
following primary antibodies for 18 h at 4 °C: mouse anti-TH (1:1000;
Millipore, Temecula, CA, USA), rabbit anti-glial fibrillary acidic protein
(GFAP) (1:500; Novus Biologicals, Littleton, CO, USA), or mouse anti-
MT-1/-2 antibodies (1:50; Dako Cytomation) diluted in 10 mM PBS
containing 0.1% Triton X-100 (Wako Pure Chemical Corporation,
Osaka, Japan) (0.1% PBST). The secondary antibodies used were goat
anti-mouse IgG conjugated to Alexa Fluor 594 (Invitrogen) or goat anti-
rabbit IgG conjugated to Alexa Fluor 488 (Invitrogen). Cells were then
counterstained with Hoechst 33342 nuclear stain.
For preparation of brain slices, mice were perfused with ice-cold
saline followed by a fixative containing 4% PFA under deep pento-
barbital anesthesia (80 mg/kg, i.p.). Perfused brains were removed and
post-fixed for 24 h in 4% PFA. Following cryoprotection in 15% sucrose
in PB for 48 h, brains were snap-frozen with powdered dry ice and 20-
μm-thick coronal sections were cut on a cryostat at levels containing the
mid-striatum (+0.6 to +1.0 mm from the bregma) and the SNpc (−2.8
to −3.0 mm from the bregma). Striatal and SNpc sections were in-
cubated in 1% normal goat serum for 30 min at RT, then reacted with
mouse anti-MT-1,2 (1:100, DAKO), rabbit anti-MT-1,2 (1:500; Frontier
Institute, Hokkaido, Japan) rabbit anti-GFAP (1:20,000, Novus
Biologicals), mouse anti-GFAP (1:10,000; Millipore), rabbit anti-S100β
(1:5000; Dako Cytomation) or mouse anti-S100β (1:10,000; Sigma
Aldrich) antibodies diluted in 0.2% PBST for 18 h at 4 °C. After washing
in 0.2% PBST, slices were reacted with Alexa Fluor 594- or Alexa Fluor
488-conjugated secondary antibodies, as appropriate. All slides were
analyzed using a fluorescence microscope (Olympus, Tokyo, Japan) and
a cellSens software imaging system (Olympus) using a mercury lamp
through a 470–495 nm, 530–550 nm, or 360–370 nm band-pass filter to
excite Alexa Fluor 488, Alexa Fluor 594, or Hoechst dye, respectively.
Light emitted from Alexa Fluor 488, Alexa Fluor 594, or Hoechst was
collected through a 510–550 nm band-pass filter, a 590 nm long-pass
filter, or a 420 nm long-pass filter, respectively. Confocal laser micro-
scope (ZEISS, Oberkochen, Germany) and ZEN software imaging system
(ZEISS) were used to confirm the colocalization of MT-1,2 and GFAP- or
S100β-positive astrocytes.
For immunostaining of TH in the SNpc, brain slices were treated
with 0.5% H2O2 (Wako Pure Chemical Corporation) for 30 min at RT,
blocked with 1% normal goat serum for 30 min, and incubated with
anti-TH rabbit polyclonal antibody (1:1,000, Millipore) diluted in 0.2%
PBST for 18 h at 4 °C. Slices were incubated with biotinylated goat anti-
rabbit IgG (1:1000; Vector Laboratories, Burlingame, CA, USA) for 2 h
followed by avidin-biotin peroxidase complex (1:2000; Vector
Laboratories) for 1 h at RT. TH-immunopositive signals were visualized
by 3,3′-diaminobenzidine tetrahydrochloride (Sigma-Aldrich), nickel
(Wako Pure Chemical Corporation), and H2O2.
For analysis of proliferative activity induced by rotigotine, striatal
astrocyte cultures were counterstained with Hoechst 33342 nuclear stain
and counted cell number in 8 fields/well chosen arbitrarily under × 400
magnification. Numbers of MT- and GFAP-immunopositive cells in cell
cultures were counted in 8–18 fields/well chosen arbitrarily under × 200
magnification, and expressed as the percentages of MT-immunopositive
astrocytes to total cell number. The integrated density of MT was calcu-
lated as follows: integrated density (signal density – background den-
sity) × area of positive signal. TH-immunopositive cells in cultured cells
were counted under a microscope in all areas of each chamber slide.
Cells immunopositive for MT-1,2, GFAP, or S100β in the dorsal
striatum of normal ICR mice or parkinsonian mice were counted
manually using a microscope at a magnification of × 200. The number
of MT-1,2-, GFAP-, or S100β-positive cells and the ratio of MT-1,2-po-
sitive cells to GFAP- or S100β-positive cells were evaluated in each
section. The number of TH-immunopositive neurons in the SNpc was
counted manually under a microscope at × 100 magnification. The
boundary between the SNpc and ventral tegmental area was defined by
a line extending dorsally from the most medial boundary of the cerebral
peduncle. The ratio of lesion area to the intact side was evaluated. No
blinding was performed in the counting of immunopositive cell number
and measurement of the immunoreactivity. Broken immunostained
slices were excluded from the quantitative analyses.
2.8. Western blot analysis
Nuclear lysates from cultured striatal astrocytes were extracted and
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prepared using NE-PER Nuclear and Cytoplasmic Extraction Reagents
(Thermo Fisher Scientific Inc., Rockford, IL) according to the protocol
provided with the kit. Total cell lysates from ventral midbrain of mice
extracted with RIPA buffer (1 mM PBS, pH 7.4, 1% Nonident P-40,
0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS)) con-
taining phenyl methy lsulfonyl fluoride (PMSF). Western blot analysis
was performed as described previously (Miyazaki et al., 2013). In brief,
proteins were separated on 10% SDS polyacrylamide gels (Bio-Rad,
Hercules, CA, USA) and electrophoretically transferred to poly-
vinylidene difluoride membranes (Hybond P, GE Healthcare, UK,
Buckinghamshire, UK) at 20 mA/membrane for 60 min. The mem-
branes were pre-incubated with blocking buffer (Block-Ace; DS Bio
Pharma Medical, Tokyo, Japan), and incubated with rabbit polyclonal
anti-nuclear factor erythroid 2-related factor (Nrf2) (1:100; Santa Cruz
Biotechnology, Santa Cruz, CA, USA), goat polyclonal anti-Lamin B
(1:200; Santa Cruz), rabbit polyclonal anti-TH (1:1000; Millipore) or
mouse monoclonal anti α-tubulin (1:2000; Sigma-Aldrich) antibodies.
After washing with 20 mM Tris-buffered saline containing 0.1% tween
20 (Wako Pure Chemical Corporation), the blots were incubated with
the corresponding horseradish peroxidase-conjugated secondary anti-
bodies. Signals were visualized via chemiluminescence using an ELC
Western blotting detection system (GE Healthcare). Images were ob-
tained and quantified using a FUJIFILM Luminescent Image Analyzer
LAS-3000 (FUJIFILM, Tokyo, Japan) and Multi Gauge (v 3.0) software.
For quantitative analysis, the signal ratio of Nrf2 (relative chemilumi-
nescence unit) to that of constitutively expressed Lamin B or TH to α-
tubulin protein was calculated to normalize for loading and transfer
artifacts. The nuclear fraction for Western blot analysis with low con-
centration was excluded prior to electrophoresis.
2.9. Enzyme-linked immunosorbent assay (ELISA)
Levels of MT-1 in cultured astrocytes and striatal tissue of parkin-
sonian mice were measured by enzyme-linked immunosorbent assay
(ELISA) with mouse MT-1 ELISA kit (SEB199Mu; Cloud-Clone Corp.,
Katy, TX, USA) according to the manufacturer's protocol. To extract
total cell lysate from cultured astrocytes or striata of parkinsonian mice
for ELISA, cells or tissues were homogenized using RIPA buffer con-
taining PMSF. After centrifugation to remove cellular debris, the su-
pernatants were stored at −80 °C until analyses. Protein concentration
were determined using the Lowry-based Bio-Rad DC protein assay kit
(Bio-Rad) with bovine serum albumin as a standard.
2.10. Statistical analysis
Values were expressed as means ± SEM. Differences between
groups were examined for statistical significance using one-way ana-
lysis of variance (ANOVA) followed by post-hoc Fisher's PLSD test. A p
value less than 0.05 was considered statistically significant. The sample
size in our study was determined based on our previous reports
(Miyazaki et al., 2013).
Fig. 1. Effects of rotigotine treatment on astro-
cyte proliferation and MT-1,2 expression.
Cultured striatal astrocytes were treated with roti-
gotine (0.01, 0.1, 1 μM) for 24 h. (A) Number of
GFAP-positive astrocytes after rotigotine treatment.
Each value is represented as the mean ± SEM
(n = 3), expressed as a percentage of the control.
(B) Representative photomicrographs of MT-1,2 and
GFAP double immunostaining. Scale bar: 50 μm. (C)
Photomicrographs of confocal laser microscope.
Scale bar: 100 μm. (D, E) Rotigotine upregulated
MT-1,2 expression in astrocytes. (D) Ratio of MT-
1,2-immunopositive astrocytes to total cells. (E)
Integrated density of MT-1,2 immunoreactivity.
Data are expressed as means ± SEM (n = 3).
*p < 0.05, **p < 0.01 vs. control group.
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3. Results
3.1. Rotigotine promoted astrocyte proliferation and upregulated MT-1,2
expression
Treatment with rotigotine (0.1 or 1 μM) significantly increased the
number of striatal astrocytes in cultured cells (Fig. 1A). Rotigotine also
upregulated MT-1,2 in striatal astrocytes (Fig. 1B-E). We confirmed
colocalization of GFAP and MT-1,2 signals using confocal laser micro-
scope (Fig. 1C). The number of MT-1,2-positive astrocytes is shown in
Fig. 1D and MT-1,2-immunoreactivity is shown in Fig. 1E. These results
suggested that rotigotine promoted astrocyte proliferation and
upregulated astrocytic antioxidative property in astrocyte cultures.
3.2. Rotigotine induced MT-1,2 expression and Nrf2 nuclear translocation
via astrocyte 5-HT1A receptors
To examine whether rotigotine upregulated MT-1,2 in astrocytes via
5-HT1A receptors, striatal astrocyte cultures were treated with rotigo-
tine (1 μM) and/or the 5-HT1A antagonist WAY100635 (10 nM) for
24 h. WAY100635 can bind to the 5-HT1A receptor with high affinity
and selectivity. It is reported that the binding activity of WAY100635 is
greater than 100-fold selectivity relative to binding at other 5-HT re-
ceptor subtypes and major neurotransmitter receptor, reuptake and ion
Fig. 2. Rotigotine upregulated MT-1,2 expres-
sion and promoted nuclear translocation of Nrf2
in astrocytes via 5-HT1A receptors. (A–D) Effects
of treatment with rotigotine and/or WAY100635 on
MT-1,2 expression in astrocytes. Cultured striatal
astrocytes were treated with rotigotine (1 μM) and/
or WAY100635 (10 nM) for 24 h. (A)
Representative photomicrographs of MT-1,2 and
GFAP double immunostaining. Scale bar: 50 μm. (B)
Ratio of MT-1,2-immunopositive astrocytes to total
cells. (C) Integrated density of MT-1,2 im-
munoreactivity. Data are expressed as
means ± SEM (n = 3). (D) Changes in MT-1
content in cultured astrocytes after treatment with
rotigotine (1 μM) and/or WAY100635 (10 nM) for
24 h. MT-1 content was determined by ELISA. Data
expressed as means ± SEM (n = 6). (E) Effects of
treatment with rotigotine and/or WAY100635 on
nuclear Nrf2 expression in astrocytes. Data are
means ± SEM (n = 4–6). *p < 0.05,
***p < 0.001 vs. control group, #p < 0.05,
##p < 0.01, ###p < 0.001 vs. the rotigotine-
treated group.
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channel sites (Forster et al., 1995). Simultaneous treatment with
WAY100635 almost completely blocked rotigotine-induced MT-1,2
expression as shown in the results of MT-1,2- and GFAP-double im-
munostaining (Fig. 2A–C). In this study, we measured MT-1,2 levels
using total cell lysates from cultured astrocytes by ELISA. Rotigotine
significantly upregulated MT levels in astrocytes, but the MT upregu-
lation was not significantly inhibited by WAY100635. (Fig. 2D). MT-1,2
gene expression is regulated by the transcriptional factor Nrf2 (Shih
et al., 2003). In the present study, we examined Nrf2 levels in nuclei of
astrocytes after 6 h treatment with rotigotine (1 μM) and WAY100635
(10 nM) by Westernblot analysis. Nrf2 levels were significantly in-
creased by rotigotine treatment, and nuclear translocation of Nrf2 was
completely blocked by WAY100635 (Fig. 2E). These results suggested
that rotigotine-induced Nrf2 nuclear translocation and MT upregulation
occurred through astrocyte 5-HT1A receptor signaling.
3.3. Rotigotine required striatal astrocytes to protect dopaminergic neurons
To examine the role of astrocytes on neuroprotective effects of ro-
tigotine against dopaminergic neurodegeneration, enriched
mesencephalic neuronal cultures or mesencephalic neuronal and
striatal astrocyte cocultures were treated with rotigotine following by
oxidative stress induced by 6-OHDA exposure (Fig. 3A). In enriched
neuronal cultures, rotigotine failed to prevent reduction of TH-positive
dopaminergic neurons following 6-OHDA exposure (Fig. 3B and C and
Suppl. Fig. 1). Conversely, in neuronal and astrocyte cocultures, roti-
gotine exerted protective effects against 6-OHDA-induced damage of
neuritis and reduction of dopaminergic neurons (Fig. 3B, D and Suppl.
Fig. 1). These results suggested that neuroprotective effects of rotigo-
tine are mediated by astrocytes.
3.4. Secreted MTs from rotigotine-treated astrocytes via 5-HT1A receptor
protected dopaminergic neurons against 6-OHDA toxicity
To investigate whether secreted molecules from rotigotine-treated
astrocytes can protect dopaminergic neurons against oxidative stress,
enriched neuronal cultures were incubated with conditioned media
from striatal astrocytes treated with or without 1 μM rotigotine (roti-
gotine-ACM/control-ACM) (Fig. 4A). Treatment with rotigotine-ACM
significantly inhibited neurite damage and reduction of TH-positive
Fig. 3. Rotigotine protected dopaminergic neu-
rons against 6-OHDA toxicity by targeting as-
trocytes. (A) Flow chart of the study design.
Mesencephalic neuronal culture or mesencephalic
neuron and striatal astrocyte coculture were treated
with rotigotine (1 μM) for 24 h, and then exposed to
6-OHDA for 24 h. Cells were fixed and im-
munostained for TH. (B) Morphological change of
dopaminergic neurons 24 h after 6-OHDA exposure.
Scale bar: 50 μm. TH-positive cell number in en-
riched mesencephalic neuronal cultures (C) or me-
sencephalic neuronal and striatal astrocyte co-
cultures (D). Each value is presented as the
mean ± SEM (n = 3), expressed as percentage of
control. **p < 0.01, ***p < 0.001 vs. each con-
trol group, ##p < 0.01, ###p < 0.001 between
the two indicated groups.
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neurons following 6-OHDA exposure. Furthermore, the protective ef-
fects of rotigotine-ACM were completely annulled by WAY100635
treatment (Fig. 4B, D, F and Suppl. Fig. 2), suggesting that rotigotine
promoted secretion of neuroprotective molecules from astrocytes via 5-
HT1A receptors. MT-1,2 are produced predominantly in astrocytes, and
extracellular MTs secreted from astrocytes protect dopaminergic neu-
rons from damage (Miyazaki et al., 2013). Therefore, we examined
involvement of MT-1,2 in rotigotine-mediated neuroprotection. Anti-
MT-1,2 antibody was added to rotigotine-ACM, and neuronal cultures
were treated with rotigotine-ACM containing MT-1,2 antibody followed
by 6-OHDA exposure (Fig. 4C). Incubation of rotigotine-ACM with anti-
MT-1,2 antibody completely blocked the neuroprotective effects of ro-
tigotine-ACM (Fig. 4E, G and Suppl. Fig. 3). These results suggested that
rotigotine exhibits dopaminergic neuroprotection by promoting MT-1,2
secretion from astrocytes via 5-HT1A receptors on astrocytes.
3.5. Rotigotine upregulated MT-1,2 expression in striatal astrocytes in
normal mice
To examine whether rotigotine upregulated MT-1,2 expression in
astrocytes in vivo, healthy ICR mice were subcutaneously injected with
rotigotine (0.125, 0.25, 0.5 mg/kg/day) for 7 days (Fig. 5A). Striatal
sections were double immunostained with the astrocyte markers S100β
and MT-1,2. MT-1,2 signals were colocalized with S100β-positive as-
trocytes (Fig. 5B). The number of MT-1,2-positive astrocytes (Fig. 5C
and D) and the ratio of MT-1,2-positive cells to S100β-positive astro-
cytes (Fig. 5E) were significantly increased following repeated rotigo-
tine administration.
3.6. Rotigotine protected dopaminergic neurons against neurodegeneration
in parkinsonian mice via 5-HT1A receptor
Rotigotine (0.125, 0.25, 0.5 mg/kg) was administered to 6-OHDA-
Fig. 4. Rotigotine promoted MT-1,2 secretion
from astrocytes to protect dopaminergic neu-
rons via 5-HT1A receptors. (A–C) Flow chart of
the study design. Rotigotine and/or WAY100635
were added to astrocytes cultures and incubated for
24 h. Astrocyte conditioned media (ACM) were
collected, and mesencephalic neurons were pre-
treated with ACM (control-ACM, rotigotine-ACM, or
WAY100635+rotigotine-ACM) for 24 h prior to 6-
OHDA exposure (A, B). Anti-MT-1,2 antibody
was added to rotigotine-ACM to neutralize
secreted MT-1,2 from rotigotine-treated astrocytes.
Mesencephalic neurons were treated with rotigo-
tine-ACM containing anti-MT-1,2 antibody for 24 h,
and then exposed to 6-OHDA (A, C). (D, E)
Morphological change of dopaminergic neurons
24 h after 6-OHDA exposure treated with rotigotine-
ACM and/or WAY100635 (D) or rotigotine-
ACM + MT-1,2 antibody (E). Scale bar: 50 μm. (F)
Cell viability of TH-positive dopaminergic neurons
after treatment with rotigotine-ACM and/or
WAY100635. Neuroprotective effects of condi-
tioned media from rotigotine-treated astrocytes
(rotigotine-ACM) were blocked by WAY100635
treatment (WAY100635+rotigotine-ACM). (G)
Incubation of rotigotine-ACM with anti-MT-1,2 an-
tibody (rotigotine-ACM + MT-1,2 Ab) blocked
neuroprotective effects of rotigotine-ACM. Data are
presented as means ± SEM (n = 4). **p < 0.01,
***p < 0.001 vs. each control group,
###p < 0.001 between the two indicated groups.
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injected parkinsonian mice to examine neuroprotective effects of roti-
gotine in vivo (Fig. 6A). TH-positive dopaminergic neurons in the SNpc
were significantly decreased in the lesioned side of parkinsonian mice.
Rotigotine administration (0.5 mg/kg) significantly ameliorated dopa-
minergic neuronal loss in the SNpc (Fig. 6B and C). To examine whether
the 5-HT1A receptor is involved in the neuroprotective effects of roti-
gotine in parkinsonian mice, rotigotine (0.25 or 0.5 mg/kg/day, s.c.)
and/or WAY100635 (0.25 or 0.5 mg/kg/day, i.p.) were administered to
6-OHDA-treated parkinsonian mice for 7 days (Fig. 7A). Rotigotine
(0.25, 0.5 mg/kg) prevented reduction of TH-positive neurons in the
lesioned side of the SNpc. Neuroprotective effects of rotigotine (0.25,
0.5 mg/kg) were blocked by co-administration of WAY100635 (0.5 mg/
kg) (Fig. 7B–G). These results suggested that rotigotine protected do-
paminergic neurons in parkinsonian mice by targeting 5-HT1A re-
ceptors. We also performed TH Western blot analysis using total cell
lysate from midbrain tissues containing SNpc of parkinsonian mice after
treatment rotigotine (0.25 mg/kg) and/or WAY100635 (0.25, 0.5 mg/
kg). TH expression in the lesioned side of SNpc was decreased by 30%
in contrast to control side. Rotigotine treatment showed neuroprotec-
tive tendency, but this did not reach significance (Suppl. Fig.4).
3.7. Effects of administration of rotigotine and/or WAY100635 on MT-1,2
expression in astrocytes in the striatum of parkinsonian mice
To examine whether rotigotine increased astrocyte MT-1,2 expres-
sion in parkinsonian mice, we double immunostained for S100β and
MT-1,2 in striatal sections of parkinsonian mice treated with rotigotine
(0.125, 0.25, 0.5 mg/kg). Rotigotine (0.25 mg/kg/day, s.c.) adminis-
tration for 7 days significantly increased the number of MT-1,2-positive
astrocytes (Suppl. Fig. 5A and B) and the ratio of MT-1,2-positive cells/
S100β-positive cells in control and lesioned side (Suppl. Fig. 5C). We
confirmed colocalization of MT-1,2 and S100β-positive astrocytes in the
striatum of parkinsonian mice (Suppl. Fig. 5D). MT induction by roti-
gotine (0.25 mg/kg/day) treatment in striatal astrocytes was blocked
by co-administration of WAY100635 (0.25, 0.5 mg/kg/day, i.p.)
(Fig. 8A–D). It is well known that astrocytes become hypertrophic (i.e.,
reactive astrocytes) and accumulate in the brain during progression of
neurodegenerative diseases. Reactive astrocytes express high levels of
GFAP in vivo. Therefore, we explored MT-1,2 expression in GFAP-po-
sitive reactive astrocytes. Accumulation of GFAP-positive astrocytes
was observed in the lesioned side of parkinsonian mice, and MT-1,2
Fig. 5. Effects of rotigotine treatment on MT-1,2
expression in astrocytes in the striatum of
normal mice. (A) Flow chart of the study design.
Rotigotine (0.125, 0.25, 0.5 mg/kg/day) or vehicle
(2% DMSO in corn oil) was administered sub-
cutaneously to healthy ICR mice (male, 8 weeks old)
for 7 days. Mice were perfused with a fixative one
day after the final administration. (B) Images of
confocal laser microscope. Scale bar: 100 μm. (C)
Representative photomicrographs of MT-1,2 and
S100β double immunostaining using striatal slices.
Scale bar: 100 μm. (D) Number of S100β- and MT-
1,2-positive cells. (E) Ratio of MT-1,2 im-
munopositive astrocytes to total cells. Each value is
presented as the mean ± SEM (n = 5). *p < 0.05,
**p < 0.01, ***p < 0.001 vs. the vehicle-treated
group.
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signals were colocalized with GFAP-positive astrocytes (Fig. 9A and B).
Rotigotine (0.25 mg/kg/day) treatment significantly increased MT-1,2
expression in reactive astrocytes, and WAY100635 (0.25, 0.5 mg/kg/
day) completely blocked this effect (Fig. 9C and D). Repeated rotigotine
(0.5 mg/kg/day) administration did not induce MT-1,2 expression in
the striatum of parkinsonian mice, and WAY100635 (0.5 mg/kg/day)
had no effect on MT expression (Suppl. Fig. 6A–C). Furthermore, we
measured MT-1 content by ELISA using striatal total cell lysate from
tissues of parkinsonian mice treated with rotigotine (0.25 mg/kg) and/
or WAY100635 (0.25, 0.5 mg/kg). There was a tendency to increase in
MT content on the lesioned side of parkinsonian mice, but rotigotine
failed to induce further increase in MT expression (Suppl. Fig. 7). To
examine effects of rotigotine administration on astrocytic MT-1,2 ex-
pression in the SNpc, we performed double immunostaining of MT-1,2
and S100β or GFAP using slices of SNpc of parkinsonian mice ad-
ministered with rotigotine (0.25 mg/kg) and WAY100635 (0.25 or
0.5 mg/kg). There was no change in MT-1,2 expression in the astrocytes
of SNpc in any groups (Suppl. Figs. 8, 9). These results suggested that
rotigotine induced MT-1,2 expression in striatal astrocytes, and pro-
tected dopaminergic neurons via 5-HT1A receptor signaling in parkin-
sonian mice.
4. Discussion
In the present study, we demonstrated dopaminergic neuroprotec-
tive effect of rotigotine via 5-HT1A receptor in parkinsonian models.
Rotigotine administration prevented dopaminergic neurodegeneration
in parkinsonian mice, which were assessed by counting TH-positive
cells. However, the results of TH Western blot analysis using tissue
samples showed neuroprotective tendency, but there was no sig-
nificance. By immunohistochemistry, TH-positive signal in each neuron
in the lesioned side of 6-OHDA-injected mice was stronger than that in
the control side. These observations suggest compensatory increase of
TH expression in the lesioned-side SN of parkinsonian mice. Western
blot analysis reflects expression of TH protein but not neuronal survival.
Therefore, we suppose it is difficult to reproduce the results of TH
immunostaining by Western blot analysis.
We showed that upregulation of MT-1,2 in astrocytes could be in-
volved in rotigotine-mediated neuroprotection in this study. MT is a
cysteine-rich protein, which has strong antioxidative, anti-apoptotic,
and anti-inflammatory properties (Giralt et al., 2002; Murakami et al.,
2014; Pan et al., 2013; Penkowa, 2006; Ruttkay-Nedecky et al., 2013).
In the brain, two major isoforms, MT-1 and -2, are expressed mainly in
astrocytes and secreted in response to oxidative stress (Chung et al.,
2004). We previously demonstrated that astrocytes produced MT-1,2 in
response to excess DA-induced oxidative stress, and extracellular MT-
1,2 protected dopaminergic neurons against DA-induced neurotoxicity
(Miyazaki et al., 2011). In addition, MT-1 binds DA quinone, a dopa-
minergic neuron-specific oxidative stress product formed by DA oxi-
dation, and can protect dopaminergic neurons against DA quinone
neurotoxicity (Asanuma et al., 2003; Graham, 1978; Hastings et al.,
1996; Miyazaki et al., 2007; Rabinovic and Hastings, 1998). It is well
known that 6-OHDA induces dopaminergic neurotoxicity via reactive
oxygen species. Previous studies reported that 6-OHDA also produce p-
quinone by auto-oxidation, played a pivotal role in 6-OHDA-induced
neurotoxicity, and glutathione (GSH) conjugated with p-quinone and
provided neuroprotection (Izumi et al., 2005). Taken together with
these previous reports, it is suggested that up-regulation of MT-1,2
expression induced by rotigotine can provide neuroprotection against
oxidative stress-induced dopaminergic neurodegeneration. It is also
supposed by a previous report, which demonstrated that rotigotine
decreased reactive oxygen species in rotenone-treated primary cultured
cells from midbrain (Radad et al., 2014). The involvement of up-reg-
ulation of anti-oxidative property in neuroprotective effects of rotigo-
tine would be examined in the future study. In this study. In this study,
we showed that MT expression was increased after rotigotine treatment
via 5-HT1A receptor, which were assessed by counting the number of
MT-1,2-positive astrocytes. Unlike the results of immunohistochemistry
Fig. 6. Neuroprotective effects of
rotigotine administration against
dopaminergic neurodegeneration in
parkinsonian mice. (A) Flow chart of
the study design. 6-OHDA was ad-
ministered to the right striatum of ICR
mice (male, 8 weeks old) to prepare
parkinsonian mice. Fourteen days after
6-OHDA injection, apomorphine rota-
tion test was performed to confirm de-
velopment of parkinsonism. Rotigotine
(0.125, 0.25, 0.5 mg/kg/day) or ve-
hicle (2% DMSO in corn oil) was ad-
ministered subcutaneously to the par-
kinsonian mice for 7 days.
Parkinsonian mice were perfused with
a fixative one day after the final ad-
ministration. (B) Representative pho-
tomicrographs of TH immunostaining
in the SNpc of parkinsonian mice after
repeated administration of rotigotine
for 7 days. Scale bar: 200 μm. (C) Ratio
of nigral TH-immunopositive cells in
the lesioned side to the control side of
parkinsonian mice after treatment with
rotigotine (0.125, 0.25, 0.5 mg/kg/day,
s.c.) or vehicle (2% DMSO in corn oil)
for 7 days. Each value is presented as
the mean ± SEM (n = 5). *p < 0.05,
**p < 0.01 vs. the control side of each
group, #p < 0.05 vs. the vehicle-
treated group.
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using brain slices, ELISA showed increasing tendency of MT content in
the lesioned-side striatum of parkinsonian mice, and rotigotine
(0.25 mg/kg) failed to induce further increase in MT expression. As
mentioned above, MT-1,2 are expressed mainly in astrocytes and pro-
tein secreted from astrocytes are consumed by neurons to reduce oxi-
dative stress. Therefore, we suppose that it is difficult to detect changes
in MT expression using tissue homogenates of parkinsonian mice. As
shown in this study, MT-1,2 were induced specifically in GFAP-positive
reactive astrocyte. Because astrocytes were activated dramatically in
the lesioned-side striatum of 6-OHDA-injected mice, we could observe
MT upregulated at least in the lesioned side.
We demonstrated that rotigotine promoted Nrf2 nuclear
translocation via astrocyte 5-HT1A receptor, resulting in increased MT-
1,2 expression. Nrf2 is a master transcription factor, which responds to
oxidative stress and induces various antioxidative molecules including
MT-1,2 (Miyazaki et al., 2011; Suzuki et al., 2013a, 2013b). GSH is also
synthesized in astrocytes regulated by Nrf2 and secreted into the ex-
tracellular space to protect neurons against oxidative stress. Previous
studies showed that GSH levels are lower in the SN of PD patients
compared to those in control subjects (Jenner et al., 1992; Riederer
et al., 1989; Sian et al., 1994; Sofic et al., 1992). Therefore, we ex-
amined GSH content in conditioned media from roigotine-treated as-
trocytes. However, GSH levels in rotigotine-ACM were not different
from levels in control-ACM (data not shown).
Fig. 7. Rotigotine protected dopaminergic neu-
rons via 5-HT1A receptors in parkinsonian mice.
(A) Flow chart of the study design. Parkinsonian
mice were administrated with WAY100635 (0.25,
0.5 mg/kg/day, i.p.) or vehicle (saline) 1 h prior to
rotigotine treatment (0.25, 0.5 mg/kg/day, s.c.).
One day after the final administration, mice were
perfused with a fixative. (B, C, F) Effects of admin-
istration of rotigotine (0.25 mg/kg/day, s.c.) and/or
WAY100635 (0.25, 0.5 mg/kg/day, i.p.) for 7 days
on nigral TH-positive neurons in parkinsonian mice.
(B) Representative photomicrographs of TH im-
munostaining in the SNpc. Scale bar: 200 μm. (C)
High magnification images of (B). Scale bar:
100 μm. (F) Ratio of TH-immunopositive cells in the
lesioned side to the control side. Each value is pre-
sented as the mean ± SEM (n = 6–7 mice per
group from one independent experiment).
**p < 0.01 vs. the control side of each group,
#p < 0.05 between the two indicated groups. (D,
E, G) Effects of administration of rotigotine
(0.5 mg/kg/day, s.c.) and/or WAY100635 (0.5 mg/
kg/day, i.p.) for 7 days on nigral TH-positive neu-
rons in parkinsonian mice. (D) Representative mi-
crographs of TH immunostaining in the SNpc. Scale
bar: 200 μm. (E) High magnification images of (D).
Scale bar: 100 μm. (G) Ratio of TH-immunopositive
cells in the lesion side to the control side. Each value
is presented as the mean ± SEM (n = 5).
#p < 0.05 between the two indicated groups.
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Previously, we reported that treatment with 5-HT1A full agonist
promoted astrocyte proliferation via secretion of S100β in vitro and in
vivo (Miyazaki et al., 2013). S100β is a calcium binding protein and
expressed primarily in astrocytes. Stimulation of 5-HT1A receptor on
astrocytes promotes S100β secretion, and extracellular S100β exerts
autocrine effects that promote astrocyte proliferation. To assess effect of
rotigotine on astrocyte proliferation, we counted astrocytes in cultured
cells or normal or parkinsonian mice. In the present study, we used anti-
GFAP and anti-S100β antibodies to detect astrocytes by im-
munohistochemistry. In cell cultures, all astrocytes express GFAP, so we
counted GFAP-positive cells. On the other hands, an anti-GFAP anti-
body detected mainly fibrous activated astrocytes in the brain of mice.
To assess all types of astrocytes, including protoplasmic astrocytes in
vivo, we used anti-S100β antibody. Treatment with rotigotine (0.1,
1 μM) increased the number of GFAP-positive cultured astrocytes. Ro-
tigotine also showed the increasing tendency of S100β-positive astro-
cyte number in normal mice and control side of parkinsonian mice.
However, the number of GFAP-positive activated astrocytes was not
changed by rotigotine. These results suggested that rotigotine has weak
proliferation effect of astrocyte, but not astrocyte activation.
In this study, we used two doses of rotigotine (0.25 or 0.5 mg/kg).
In contrast to rotigotine (0.25 mg/kg)-treated group, rotigotine
(0.5 mg/kg) did not upregulate MT-1,2 expression, but the drug could
inhibit the reduction of nigral dopaminergic neurons in parkinsonian
mice. These data suggest that rotigotine may activate several neuro-
protective pathways including not only Nrf2-MT pathway but also other
pathways, which are not regulated by Nrf2, via 5-HT1A receptor. In
addition, rotigotine (0.25 mg/kg) induced MT expression rather than
rotigotine (0.5 mg/kg). In the previous study, we reported that effects
of 5-HT1A full agonist on astrocytes are not exhibited in a dose-de-
pendent manner (Miyazaki et al., 2013). There is an optimal dose of 5-
HT1A agonist to activate astrocytic antioxidative property. Taken to-
gether, we suppose rotigotine (0.5 mg/kg) may affect other neuropro-
tective pathways rather than MT upregulation. WAY100635 (0.25 mg/
kg) administration could annul rotigotine (0.25 mg/kg)-induced MT
upregulation in astrocytes, but not dopaminergic neuroprotective ef-
fect. As mentioned above, we demonstrated that rotigotine induced
Nrf2 translocation to nuclei via 5-HT1A receptor. Taken together with
these results from in vivo and in vitro, it is suggested that rotigotine
exerts neuroprotective effects by not only MT upregulation but also
other mechanisms induced by 5-HT1A receptor stimulation. We sup-
posed that WAY100635 (0.25 mg/kg) is not sufficient to block all
neuroprotective mechanisms.
Fig. 8. Rotigotine upregulated MT-1,2 expres-
sion in S100β-positive striatal astrocytes in
parkinsonian mice via 5-HT1A receptors. Effects
of administration of rotigotine (0.25 mg/kg/day,
s.c.) and/or WAY100635 (0.25, 0.5 mg/kg/day,
i.p.) for 7 days on MT-1,2 expression in striatal as-
trocytes in parkinsonian mice. We performed
double-immunostaining of S100β and MT-1,2. (A)
Images of confocal laser microscope. Scale bar:
100 μm. (B) Representative photomicrographs of
S100β and MT-1,2 double immunostaining. Scale
bar: 50 μm. (C) Number of S100β- and MT-1,2-po-
tive cells in the striatum of parkinsonian mice. (D)
Ratio of MT-1,2-positive cells to S100β-positive
cells. Data are presented as means ± SEM (n = 5).
*p < 0.05 vs. the same side of the vehicle-treated
group, #p < 0.05, ##p < 0.01 vs. the same side of
the rotigotine-treated group.
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5. Conclusion
The present study demonstrated that the anti-parkinsonian agent,
rotigotine, increased expression of antioxidant MTs in astrocytes and
protected dopaminergic neurons against oxidative stress via 5-HT1A
receptors. Furthermore, administration of rotigotine prevented dopa-
minergic neurodegeneration in parkinsonian mice. These results sug-
gested that rotigotine upregulates antioxidant molecules by targeting 5-
HT1A receptors on astrocytes, resulting in neuroprotection. Our find-
ings suggested that rotigotine may be effective as a disease-modifying
treatment for PD.
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Fig. 9. Rotigotine upregulated MT-1,2 expres-
sion in GFAP-positive astrocytes in the striatum
of parkinsonian mice via 5-HT1A receptors.
Effects of administration of rotigotine (0.25 mg/kg/
day, s.c.) and/or WAY100635 (0.25, 0.5 mg/kg/
day, i.p.) for 7 days on MT-1,2 expression in striatal
astrocytes in parkinsonian mice. We performed
double immunostaining of GFAP and MT-1,2. (A)
Images of confocal laser microscope. Scale bar:
100 μm. (B) Representative photomicrographs of
GFAP and MT-1,2 double immunostaining. Scale
bar: 50 μm. (C) Number of GFAP- and MT-1,2-po-
sitive cells in the striatum of parkinsonian mice. (D)
Ratio of MT-1,2-positive cells to GFAP-positive cells
on the lesioned side. Data are presented as
means ± SEM (n = 5). *p < 0.05 vs. the same
side of the vehicle-treated group, #p < 0.05,
##p < 0.01 vs. the same side of the rotigotine-
treated group.
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